3D alloy nanostructure and plasmonic biosensor comprising same

A 3D alloy nanostructure-based plasmonic biosensor enhances sensitivity and specificity for sepsis biomarker detection, addressing the limitations of current sepsis diagnosis methods by providing precise and rapid differentiation of organ failure types and severity prediction.

WO2026127649A1 Publication Date: 2026-06-18KOREA UNIV RES & BUSINESS FOUND +1
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
KOREA UNIV RES & BUSINESS FOUND
Filing Date
2025-12-10
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Current methods for diagnosing sepsis are time-consuming, lack precision, and struggle to differentiate between infectious and non-infectious organ failure, leading to ineffective antibiotic administration and potential antibiotic resistance, while existing SERS-based biosensors face challenges in distinguishing biomarkers due to background noise in clinical samples.

⚗Method used

A 3D alloy nanostructure comprising gold-silver alloy nanofillers with gold nanoparticles on top, forming densely packed nanogaps, used in a plasmonic biosensor for precise detection of sepsis biomarkers like PD-L1, CD123, HLA-DR, and ChiT, utilizing a sandwich assay and machine learning for differential diagnosis.

🎯Benefits of technology

The biosensor provides high sensitivity and specificity for detecting sepsis biomarkers, enabling accurate diagnosis, differentiation of organ failure types, and predicting severity, with improved signal-to-noise ratio and rapid analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to a 3D alloy nanostructure and a plasmonic biosensor comprising same. According to the present invention, it is possible to provide a nanostructure with significantly improved sensitivity and selectivity through a uniform structure in which nanogaps are densely formed, and it is possible to provide a plasmonic biosensor capable of detecting a biomarker present in a trace amount in a biological sample with high precision through the nanostructure. In addition, since the plasmonic biosensor can detect sepsis biomarkers with high sensitivity and specificity, the plasmonic biosensor can be usefully employed in various clinical applications such as sepsis diagnosis, differentiation of organ failure types, sepsis severity prediction, and post-treatment.
Need to check novelty before this filing date? Find Prior Art